» Articles » PMID: 30573634

Deep Functional Immunophenotyping Predicts Risk of Cytomegalovirus Reactivation After Hematopoietic Cell Transplantation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2018 Dec 22
PMID 30573634
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Cytomegalovirus (CMV) is the most common viral infection in hematopoietic cell transplantation (HCT) recipients. We performed deep phenotyping of CMV-specific T cells to predict CMV outcomes following allogeneic HCT. By using 13-color flow cytometry, we studied ex vivo CD8 T-cell cytokine production in response to CMV-pp65 peptides in 3 clinically distinct subgroups of CMV-seropositive HCT patients: (1) (n = 19): did not have evidence of CMV DNAemia on surveillance testing; (2) (n = 16): spontaneously resolved low-grade CMV DNAemia without antiviral therapy; and (3) (NC; n = 21): experienced clinically significant CMV. Two CMV-specific CD8 T-cell functional subsets were strongly associated with risk of CMV: (i) the (NPS; IL-2IFN-γTNF-αMIP-1β), found at increased levels among NC; and (ii) the (PS; IL-2IFN-γTNF-αMIP-1β) found at low levels among NC. High levels of the NPS and low levels of PS were associated with an increased 100-day cumulative incidence of clinically significant CMV infection (35% vs 5%; = .02; and 40% vs 12%; = .05, respectively). The highest predictive value was observed when these signatures were combined into a composite biomarker consisting of low levels of the PS and high levels of the NPS (67% vs 10%; < .001). After adjusting for steroid use or donor type, this composite biomarker remained associated with a fivefold increase in the risk of clinically significant CMV infection. CMV-specific CD8 T-cell cytokine signatures with robust predictive value for risk of CMV reactivation should prove useful in guiding clinical decision making in HCT recipients.

Citing Articles

Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation.

Xia J, Xiao Y, Gui G, Gong S, Wang H, Li X Virol J. 2024; 21(1):236.

PMID: 39350155 PMC: 11443867. DOI: 10.1186/s12985-024-02511-x.


Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.

Lin R, Anderson A, Natori Y, Raja M, Morris M, Jimenez A Blood Adv. 2024; 8(14):3813-3822.

PMID: 38838226 PMC: 11298821. DOI: 10.1182/bloodadvances.2024012922.


Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Keller M, Hanley P, Chi Y, Aguayo-Hiraldo P, Dvorak C, Verneris M Nat Commun. 2024; 15(1):3258.

PMID: 38637498 PMC: 11026387. DOI: 10.1038/s41467-024-47057-2.


Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.

Huang J, Pan Z, Wang L, Zhang Z, Huang J, Jiang C Clin Exp Med. 2024; 24(1):22.

PMID: 38280072 PMC: 10821970. DOI: 10.1007/s10238-023-01270-3.


Circulating cytokine and chemokine patterns associated with cytomegalovirus reactivation after stem cell transplantation.

Stern L, McGuire H, Avdic S, Blyth E, Gottlieb D, Patrick E Clin Transl Immunology. 2023; 12(12):e16815.

PMID: 38034080 PMC: 10684332. DOI: 10.1002/cti2.1473.